New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters

Published on 10/05/2022

ENYO is proud to share international collaborative study showing the anti-diabetic potential of the small molecule dEF2905 (M1) designed by ENYO Pharma’s drugdiscovery platform.
The study driven by Pr R. Nechushtai from the Hebrew University of Jerusalem demonstrates the efficacy of M1 in correcting defective blood glucose homeostasis in a diabetic mouse model through [2Fe-2S] cluster destabilization of mitochondrial NEET proteins. This publication also highlights the ENYO Pharma’s drug discovery platform inspired by viruses.
Publication here

Read next in 'Latest news'

• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
• Swiss NASH Foundation sponsorship